908 Devices (MASS) and Getinge announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ Maven for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MASS:
- 908 Devices price target lowered to $6 from $17 at Stifel
- 908 Devices downgraded to Market Perform from Outperform at Leerink
- 908 Devices Inc. Reports Q3 2024 Financial Results
- 908 Devices Restructures for Cost Efficiency and Growth
- 908 Devices reports Q3 EPS (84c), consensus (28c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
